Novo Nordisk A/S (ADR) (NYSE:NVO) has made an announcement that their diabetes treatment Liraglutide cuts weight and reduces health risks in obese non-diabetics. The Denmark-based healthcare company unveiled a set of new data that demonstrated that its Type 2 diabetes drug Victoza is far more effective than Roche’s Xenical in cutting weight and losing blood pressure. Novo Nordisk has already applied for the New Drug Application however; it has not been reviewed by the Food and Drug Administration panel. Novo Nordisk is into the manufacturing and marketing of pharmaceutical products and services to patients who are suffering from diabetes.

http://www.favstocks.com/novo-nordisk-ra...